ICLR
Icon·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Significant Net Income Decline
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ICLR
Icon Public Limited Company
A world-leading provider of contract clinical research services to the pharmaceutical, biotechnology and medical device
Life Science Tools and Services
--
02/04/2013
NASDAQ Stock Exchange
41,900
12-31
Common stock
South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland
--
Icon Public Limited Company is a contract research organization (" CRO ") that provides outsourced development services to the pharmaceutical, biotechnology and medical device industries on a global scale. The company specializes in strategic development, management and project analysis, which support the entire clinical development process, ranging from compound selection to Phase I to Phase IV clinical studies. The company began operations in 1990. The CRO industry provides separate product development services to the pharmaceutical, biotechnology and medical device industries. Companies in these industries outsource product development services to contract research organizations to more effectively manage the drug development process and maximize the profit potential of patent-protected and generic products at a lower cost. The contract research organization industry has evolved from a small number of companies providing limited clinical services in the 1970s to a large number of contract research organizations providing a wide range of overall research and development processes (including preclinical development, clinical trial management, clinical data management, research design, biological data analysis, aftermarket supervision, regulatory affairs services and central laboratory services). Contract research organizations are subject to applicable regulatory authorities and are required to provide these services in line with better clinical and laboratory practice.
Earnings Call
Q1/2025
Estimate EPS3.1
Actual EPS3.19
Estimate Revenue2.01B
Actual Revenue2.00B
ICON's Q1 2025: Dissecting Contradictions in Cancellation Trends and Biotech Market Dynamics
May 09,2025 03:40
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS3.18
Actual EPS3.26
Estimate Revenue1.98B
Actual Revenue2.02B
Navigating Contradictions: Insights from the 2025 Q2 Earnings Call on Market Demand, Pricing, and Cancellations
Jul 24,2025 06:29
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ICLR has released its 2025 Q3 earnings. EPS was reported at 3.31, versus the expected 3.28, beating expectations. The chart below visualizes how ICLR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ICLR has released its 2025 Q3 earnings report, with revenue of 2.04B, reflecting a YoY change of 0.63%, and net profit of 2.35M, showing a YoY change of -98.81%. The Sankey diagram below clearly presents ICLR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
